Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Key trials in prostate cancer at ASCO 2022

Arun Azad • 27 May 2022
ASCO 2022
Genitourinary Cancer Prostate Cancer
ENZAMET TheraP VISION

Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Victoria, Australia, discusses which trials in prostate cancer to look out for at ASCO 2022, including TheraP (NCT03392428), VISION (NCT03511664), and ENZAMET (NCT02446405). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Arun Azad

Novel PARPi + ARPi therapeutic combinations in 1L mCRPC: findings from clinical trials
4:02
Novel PARPi + ARPi therapeutic combinations in 1L mCRPC: findings from clinical trials
Arun Azad • 23 Oct 2023
Non-WT BRCA associated with inferior prognosis in patients with metastatic prostate cancer
4:15
Non-WT BRCA associated with inferior prognosis in patients with metastatic prostate cancer
Arun Azad • 23 Oct 2023
TALAPRO-2: exposure efficacy of talazoparib and enzalutamide in mCRPC
1:56
TALAPRO-2: exposure efficacy of talazoparib and enzalutamide in mCRPC
Arun Azad • 23 Oct 2023
TALAPRO-2: exposure-safety of talazoparib + enzalutamide in mCRPC
1:44
TALAPRO-2: exposure-safety of talazoparib + enzalutamide in mCRPC
Arun Azad • 23 Oct 2023

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals